Octave Specialty heads into Q2 results with revenues projected to jump 47.4%. The bottom line is likely to improve y/y, though the model does not signal a beat.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
PRU's Q2 results are expected to reflect strength in Retirement, Individual Life and PGIM despite pressure in Group Insurance.
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
AIZ's Q2 results are expected to benefit from growth in Global Housing and Global Lifestyle, supported by higher premiums and investment income.
Oscar Health (OSCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the latest trading session, Oscar Health, Inc. (OSCR) closed at $30.57, marking a -2.64% move from the previous day.
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
The past six months have been a windfall for Oscar Health’s shareholders. The company’s stock price has jumped 86.2%, hitting $27.70 per share. This performance may have investors wondering how to approach the situation.
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Oscar Health stock has delivered very strong returns over the past few years, yet the valuation checks present a more mixed picture that stops short of calling it a straightforward bargain. The share price has returned 269.8% over the last 3 years, which puts recent short term pullbacks into the context of a powerful longer term move. Investor expectations around Oscar Health's ability to scale its insurance platform efficiently can support the current valuation, while ongoing execution...
Zacks.com users have recently been watching Oscar Health (OSCR) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Oscar Health (OSCR) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Oscar Health and other multiline insurers may benefit from diversification, digitalization and M&A trends despite pricing pressure and inflation.
In the closing of the recent trading day, Oscar Health, Inc. (OSCR) stood at $30.61, denoting a -1.48% move from the preceding trading day.
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
Oscar Health (OSCR) leverages a tech-driven platform and innovative insurance offerings to differentiate in the ACA marketplace. OSCR exhibits strong technical momentum and maintains a 100% “Buy” opinion from Barchart. Shares are up 106% over the past year. OSCR is gaining investor attention, trading near all-time highs, and is expected...
In the most recent trading session, Oscar Health, Inc. (OSCR) closed at $31.2, indicating a +1.27% shift from the previous trading day.
In recent days, Oscar Health has drawn attention for strong revenue growth, expanding exposure to the Affordable Care Act market, and mixed analyst views on its valuation and profitability outlook. At the same time, a family trust linked to director Mario Schlosser sold and converted Class A and Class B shares under a pre-arranged trading plan, highlighting insider portfolio diversification rather than a shift in overall ownership exposure. Now we’ll examine how Oscar’s rapid revenue...
Oscar Health stock has logged a very large 3 year gain, yet recent valuation checks and analyst commentary suggest the shares may still be priced below what some investors expect for its growth profile. With the stock already reflecting strong momentum and mixed views from analysts, the question is whether the current valuation leaves enough room for further upside without stretching fundamentals. Oscar Health has returned about 277.2% over the past 3 years, which puts extra focus on whether...
Here is how Apple Hospitality REIT (APLE) and Oscar Health, Inc. (OSCR) have performed compared to their sector so far this year.
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
The latest trading day saw Oscar Health, Inc. (OSCR) settling at $31.44, representing a -2.3% change from its previous close.
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
Oscar Health, Inc. (OSCR) closed at $28.52 in the latest trading session, marking a -3.16% move from the prior day.
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how health insurance providers stocks fared in Q1, starting with Oscar Health (NYSE:OSCR).
Oscar Health, Inc. (OSCR) concluded the recent trading session at $29.16, signifying a -2.57% move from its prior day's close.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently - over the past six months, the collective 5.2% gain for healthcare stocks has fallen short of the S&P 500’s 8.5% rise.
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
Investors are still underrating this insurance disrupter.
The latest trading day saw Oscar Health, Inc. (OSCR) settling at $28.26, representing a -2.25% change from its previous close.